Evidence map›Paper›PMID 42094361›Full record

ArticlebioRxiv : the preprint server for biology2026

A High-Throughput Platform for Rapid Adaptation of DNA Aptamers to SARS-CoV-2 Evolution.

Yujie He, Zhenglin Yang, Yu-An Kuo, Yuting Wu, Diego Fonseca-Albert, Kyle K Le, Jeffrey Guo, Yanxing Wang, Anh-Thu Nguyen, Yuan-I Chen and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Yujie HeDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-6984-3052
Zhenglin YangDepartment of Chemistry, University of Texas at Austin, Austin, TX, USA.
Yu-An KuoDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Yuting WuDepartment of Chemistry, University of Texas at Austin, Austin, TX, USA.
Diego Fonseca-AlbertDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Kyle K LeDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Jeffrey GuoDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Yanxing WangDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Anh-Thu NguyenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Yuan-I ChenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Sohyun KimDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Wei-Ru ChenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Saeed SeifiDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Soonwoo HongDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-7618-9052
Trung Duc NguyenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Yinong ChenDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Pengyu RenDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.
Yi LuDepartment of Chemistry, University of Texas at Austin, Austin, TX, USA.
Hsin-Chih YehDepartment of Biomedical Engineering, University of Texas at Austin, Austin, TX, USA.

Funding

DEVELOPMENT OF A NEXT-GENERATION NUCLEIC ACID FORCE FIELDR01GM106137 · NIGMS · WASHINGTON UNIVERSITY · PI JAY PONDER, Pengyu Ren · 2013 to 2026
$3.5M
Design and Selection of Novel Metalloenzymes for Biocatalysis, Bioimaging, and Genetic EngineeringR35GM141931 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI Yi Lu · 2021 to 2026
$3.5M
Studying synaptic transmission under opioid exposure using hiPSC-derived midbrain model and hyperspectral fluorescence lifetime imagingR21DA060543 · NIDA · UNIVERSITY OF TEXAS AT AUSTIN · PI SEIDLITS, STEPHANIE KRISTIN, YEH, HSIN-CHIH · 2024 to 2025
$404k
NIDA NIH HHS R21 DA060543NIGMS NIH HHS R01 GM106137NIGMS NIH HHS R35 GM141931
6 · The paper itself

Abstract

Rapid pathogen evolution threatens public health by eroding the effectiveness of vaccines, therapeutics, and diagnostic tools. Although spike protein targeting monoclonal antibodies (mAbs) were developed within 10-12 months of the initial outbreak to serve as key theranostic agents, their redesign has struggled to keep pace with viral evolution, rendering many neutralizing antibodies ineffective. Here we demonstrate a novel platform that combines a random-rational hybrid library diversification with high-throughput

Identifiers

PMID42094361
PMCPMC13142518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.